South Korean consortium to produce 100 million doses a month of Russia’s Sputnik V vaccine

04/15/2021
Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on pinterest
Share on whatsapp
Share on email
Share on tumblr
Share on digg
Share on mix

SEOUL (Reuters) – South Korea’s Huons Global Co Ltd said on Friday it will lead a consortium to produce 100 million doses of Russia’s Sputnik V COVID-19 vaccine per month as Moscow ramps up production for supplies abroad.

The announcement comes after South Korean biotech firm GL Rapha signed a deal with Russia’s sovereign wealth fund late last year to make more than 150 million doses of Sputnik V per year.

Huons said the consortium will begin producing sample batches in August and respond flexibly to supply demands from the Russian Direct Investment Fund (RDIF).

The consortium includes three other local companies – Prestige BioPharma, Humedix and Boran Pharma – which will build a new production facility, Huons said in a statement.

Shares in Huons Global jumped 29.8% to their daily limit on Friday morning trade, versus a flat wider market.

India’s ambassador to Moscow on Friday said deliveries of Russia’s Sputnik V coronavirus vaccine to India were expected to begin before the end of April, after Indian regulators approved the shot for use on Monday.

The European Medicines Agency (EMA) is conducting a rolling review of the Russian vaccine as many European countries seek to ramp up inoculation programmes that have been hampered by delivery delays.

 

(Reporting by Sangmi Cha, Additional reporting by Joyce Lee; Editing by Lincoln Feast.)

Leave a Reply

Your email address will not be published. Required fields are marked *

Become a Contributor

If you want to submit your story, get in touch with our editorial team at [email protected] or click the button below: